Statement | 16 June 2026 Europe European Biotech Act Must Deliver Public-Interest Innovation and Equitable Access
Press release | 16 June 2026 Public investment demands public benefits: European Biotech Act must deliver for people
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 18 May 2026 Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Letter | 17 April 2026 Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Statement | 16 June 2026 Europe European Biotech Act Must Deliver Public-Interest Innovation and Equitable Access
Press release | 16 June 2026 Public investment demands public benefits: European Biotech Act must deliver for people
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Letter | 17 April 2026 Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Report | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Statement | 16 June 2026 Europe European Biotech Act Must Deliver Public-Interest Innovation and Equitable Access
Press release | 16 June 2026 Public investment demands public benefits: European Biotech Act must deliver for people
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 18 May 2026 Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Letter | 17 April 2026 Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Statement | 16 June 2026 Europe European Biotech Act Must Deliver Public-Interest Innovation and Equitable Access
Press release | 16 June 2026 Public investment demands public benefits: European Biotech Act must deliver for people
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 18 May 2026 Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Letter | 17 April 2026 Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Statement | 17 November 2014 Research and development R&D cost estimates - MSF response to Tufts CSDD study on cost to develop a new drug
Photograph by Sami Siva Press release Press release | 17 November 2014 Tropical & neglected diseases India India: MSF supports the introduction and roll-out of single-dose treatment for kala azar in Bihar State
Photograph by Martin Zinggl Press release Press release | 13 November 2014 Intellectual property and trade First trials for Ebola treatments to start at MSF sites in December 5 min
Statement | 03 November 2014 Hepatitis C Intellectual property and trade MSF responds to BMS commercial strategy for hepatitis C drug daclatasvir in developing countries 5 min
Photograph by Wendy Marijnissen Press release Press release | 30 October 2014 Tuberculosis MSF sounds alarm on practices and policies dangerously out of step with what’s needed to contain the global drug-resistant TB crisis
Photograph by Julien Rey/MSF Press release Press release | 24 October 2014 Tropical & neglected diseases Ebola: MSF urges immediate action on vaccines and treatments for frontline workers
